January 10, 2020 08:50 pm
Photo by Smith Collection/Gado/Getty Images
Original Link: https://www.theverge.com/2020/1/10/21060456/23andme-licensed-drug-developed-genetic-database-autoimmune-psoriasis-almirall
23andMe sold the rights to a drug it developed from its genetic database
Photo by Smith Collection/Gado/Getty Images
The genetics testing company 23andMe licensed the rights to a drug it developed in-house to a Spanish pharmaceutical company, Bloomberg reported. This is the first time that the company has directly sold a product it created using the genetic information collected from users.
23andMe has already shared genetic data with pharmaceutical companies. GlaxoSmithKline has the exclusive rights to use its data for drug development, and purchased a $300 million stake in the company in 2018. But those drug companies use the company’s data to create their own drugs. In this case, 23andMe identified a drug candidate and conducted animal studies on that drug internally before selling it. The Spanish company, Almirall, will take the product through...
Original Link: https://www.theverge.com/2020/1/10/21060456/23andme-licensed-drug-developed-genetic-database-autoimmune-psoriasis-almirall
Share this article:
Tweet
View Full Article
The Verge
The Verge is an ambitious multimedia effort founded in 2011More About this Source Visit The Verge